Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?

References

• Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265–71.
   PubMed Web of Science ®Google Scholar
• Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the surveillance, epidemiology, and end results database. Cancer. 2009;115(24):5761–70.
   PubMed Web of Science ®Google Scholar
• Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197–206.
   PubMed Web of Science ®Google Scholar
• Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Cefalo G, Garré ML, Massimino M, Colosimo C, Attinà G, et al. Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol. 2006;77(1):89–94.
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17(9):2762–71.
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–93.
   PubMed Web of Science ®Google Scholar
• Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16(12):3851–57.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, et al. A Phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neurooncol. 2002;4(4):261–7.
   Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–82.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
   PubMed Web of Science ®Google Scholar
• Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. Br J Cancer. 1998;78(5):652–61.
   PubMed Web of Science ®Google Scholar
• Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J Clin Oncol. 1998;16(9):3037–43.
   PubMed Web of Science ®Google Scholar
• Available from: http://ctep.cancer.gov/forms/CTCAE.pdf
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.
   Web of Science ®Google Scholar
• Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brain stem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005;103(1):133–9.
   PubMed Web of Science ®Google Scholar
• Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 2001;13(4):410–6.
   Google Scholar
• Chassot A, Canale S, Varlet P, Puget S, Roujeau T, Negretti L, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012;106(2):399–407.
   PubMed Web of Science ®Google Scholar
• Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113–8.
   PubMed Web of Science ®Google Scholar
• Chiang KL, Chang KP, Lee YY, Huang PI, Hsu TR, Chen YW, et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst. 2010;26(8):1035–41.
   PubMed Web of Science ®Google Scholar
• Kebudi R, Cakir FB, Agaoglu FY, Gorgun O, Ayan I, Darendeliler E. Pediatric diffuse intrinsic pontine glioma patients from a single center. Childs Nerv Syst. 2013;29(4):583–8.
   PubMed Web of Science ®Google Scholar
• Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst. 1999;15(10):545–53.
   PubMed Web of Science ®Google Scholar
• Donaldson S, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006;24(8):1266–72.
   PubMed Web of Science ®Google Scholar
• Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. NeuroOncology 2011;13(2):212–22.
   PubMed Web of Science ®Google Scholar
• Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44.
   PubMed Web of Science ®Google Scholar
• Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196–208.
   PubMed Web of Science ®Google Scholar